Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript describes a situation where the company is currently in the middle of copying a part of its own business that is already working into additional places where the same demand is already visible. The key elements: (1) a proven instance that works, (2) copies being stood up now, (3) demand already identified at the destination. Let's analyze the transcript. The company is Surmodics, a medical device company. They have various products and technologies. The call discusses their strategic objectives, including clinical trials, product pipeline, and commercialization. The question asks about "copying a part of its own business that is already working into additional places where the same demand is already visible." This could refer to expanding a proven product or technology into new markets, or replicating a successful business model. Looking at the transcript, management talks about their whole product solutions pipeline, their drug-coated balloon (SurVeil) with Abbott, their thrombectomy technology from Embolitech, and their various catheters. They also mention their IVD business. Is there any mention of replicating a proven instance? For example, they have a hydrophilic coating technology that is used in their products. They have royalty revenue from hydrophilic coatings. They are developing new products using that coating. But that's not exactly copying a proven business into new locations. They mention that they are progressing towards commercial agreements for their cleared products. They have .014 and .018 balloon catheters, and a microcatheter. They are in discussions with multiple parties. But that's about licensing or selling products, not about standing up additional instances of a proven operation. The question specifically asks about "copying a part of its own business that is already working into additional places where the same demand is already visible." This might refer to something like opening new manufacturing facilities, or expanding into new geographic markets with an existing product that has proven demand. But the transcript doesn't seem to describe that. Management talks about their clinical trial for SurVeil, which is ongoing. They are enrolling patients. That's not a proven instance; it's a trial. They talk about their thrombectomy technology, which is in development, not yet proven.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.